Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · IEX Real-Time Price · USD
2.550
+0.030 (1.19%)
At close: Jul 19, 2024, 4:30 PM
2.600
+0.050 (1.96%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Oramed Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for ORMP.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for ORMP is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 20, 2024 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -21.57% | May 17, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 17, 2023 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 12, 2023 |
| Aegis Capital | Aegis Capital | Strong Buy Maintains $35 → $30 | Strong Buy | Maintains | $35 → $30 | +1,076.47% | May 16, 2022 |
Financial Forecast
Revenue This Year
765.00K
from 1.34M
Decreased by -42.91%
Revenue Next Year
4.08M
from 765.00K
Increased by 433.33%
EPS This Year
-0.01
from 0.14
EPS Next Year
-0.34
from -0.01
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | 1.6M | 4.2M |
| Avg | 765,000 | 4.1M |
| Low | n/a | 3.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | 17.5% | 449.0% |
| Avg | -42.9% | 433.3% |
| Low | - | 412.4% |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | 0.08 | -0.32 |
| Avg | -0.01 | -0.34 |
| Low | -0.10 | -0.35 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | -40.0% | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.